Progression of metastatic castrate-resistant prostate cancer: Impact of therapeutic intervention in the post-docetaxel space

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Sartor, A Oliver ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AFLIBERCEPT; ANDROGEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CORTICOSTEROID; COUAA 301; DASATINIB; DOCETAXEL; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; PROVENGE; SATRAPLATIN; THALIDOMIDE; UNCLASSIFIED DRUG; ZIBOTENTAN; ANDROGEN RECEPTOR; TAXOID;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANEMIA; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; LEUKOPENIA; LOW DRUG DOSE; METASTATIC CASTRATE RESISTANT PROSTATE CANCER; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPREGULATION; DISEASE COURSE; DRUG RESISTANCE; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TAXOIDS; TREATMENT OUTCOME;

EID: 79955040539     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-18     Document Type: Review

References (51)

1. Cancer statistics, 2010. A Jemal R Siegel J Xu E Ward, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Targeting the androgen receptor pathway in prostate cancer. Y Chen CL Sawyers HI Scher, Curr Opin Pharmacol 2008 8 440 448 10.1016/j.coph.2008.07.005 18674639
3. Chemotherapy for hormone-refractory prostate cancer. M Shelley C Harrison B Coles J Stafforth T Wilt M Mason, Cochrane Database of Systematic Reviews 2006 4
4. Prostate cancer: a practical approach to current management of recurrent disease. JR Walczak MA Carducci, Mayo Clin Proc 2007 82 243 249 10.4065/82.2.243 17290734 (Pubitemid 46198485)
5. Castration-resistant prostate cancer: current and emerging treatment strategies. G Di Lorenzo C Buonerba R Autorino S De Placido CN Sternberg, Drugs 2010 70 983 1000 10.2165/10898600-000000000-00000 20481655
6. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. KN Chi A Bjartell D Dearnaley F Saad FH Schröder C Sternberg B Tombal T Visakorpi, Eur Urol 2009 56 594 605 10.1016/j.eururo.2009. 06.027 19560857
7. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. IF Tannock R de Wit WR Berry J Horti A Pluzanska KN Chi S Oudard C Théodore ND James I Turesson MA Rosenthal MA Eisenberger TAX 327 Investigators, N Engl J Med 2004 351 1502 1512 10.1056/NEJMoa040720 15470213 (Pubitemid 39315317)
8. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. DP Petrylak CM Tangen MH Hussain PN Lara Jr JA Jones ME Taplin PA Burch D Berry C Moinpour M Kohli MC Benson EJ Small D Raghavan ED Crawford, N Engl J Med 2004 351 1513 1520 10.1056/NEJMoa041318 15470214 (Pubitemid 39315318)
9. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301 [abstract]. JS De Bono CJ Logothetis K Fizazi S North L Chu KN Chi T Kheoh C Haqq A Molina HI Scher COU-AA-301 investigators, Presidential symposium at ESMO Milan, Italy 2010
10. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. JS De Bono S Oudard M Ozguroglu S Hansen JP Machiels I Kocak G Gravis I Bodrogi MJ Mackenzie L Shen M Roessner S Gupta AO Sartor TROPIC Investigators, Lancet 2010 376 1147 1154 10.1016/S0140-6736(10) 61389-X 20888992
11. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. IF Tannock D Osoba MR Stockler DS Ernst AJ Neville MJ Moore GR Armitage JJ Wilson PM Venner CM Coppin KC Murphy, J Clin Oncol 1996 14 1756 1764 8656243 (Pubitemid 26185452)
12. A randomized, double-blind, placebo controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrate-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 [abstract LBA4511]. WK Kelly SI Halab MA Carducci DJ George JF Mahoney WM Stadler MJ Morris P Kantoff JPE Monk III EJ Small, J Clin Oncol 2010 28 suppl 344S
13. The androgen axis in recurrent prostate cancer. JL Mohler CW Gregory OH Ford D Kim CM Weaver P Petrusz EM Wilson FS French, Clin Cancer Res 2004 10 440 448 10.1158/1078-0432.CCR-1146-03 14760063 (Pubitemid 38173980)
14. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. M Stanbrough GJ Bubley K Ross TR Golub MA Rubin TM Penning PG Febbo SP Balk, Cancer Res 2006 66 2815 2825 10.1158/0008-5472.CAN-05-4000 16510604
15. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. RB Montgomery EA Mostaghel R Vessella DL Hess TF Kalhorn CS Higano LD True PS Nelson, Cancer Res 2008 68 4447 4454 10.1158/0008-5472.CAN-08-0249 18519708
16. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. MJ Linja KJ Savinainen OR Saramäki TL Tammela RL Vessella T Visakorpi, Cancer Res 2001 61 3550 3555 11325816 (Pubitemid 32694958)
17. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. EA Mostaghel PS Nelson, Best Pract Res Clin Endocrinol Metab 2008 22 243 258 10.1016/j.beem.2008.01.003 18471783 (Pubitemid 351611949)
18. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. R Hu TA Dunn S Wei S Isharwal RW Veltri E Humphreys M Han AW Partin RL Vessella WB Isaacs GS Bova J Luo, Cancer Res 2009 69 16 22 19117982
19. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. S Sun CC Sprenger RL Vessella K Haugk K Soriano EA Mostaghel ST Page IM Coleman HM Nguyen H Sun PS Nelson SR Plymate, J Clin Invest 2010 120 2715 2730 10.1172/JCI41824 20644256
20. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. PA Watson YF Chen MD Balbas J Wongvipat ND Socci A Viale K Kim CL Sawyers, Proc Natl Acad Sci USA 2010 107 16759 16765 10.1073/pnas.1012443107 20823238
21. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. PW Kantoff S Halabi M Conaway J Picus J Kirshner V Hars D Trump EP Winer NJ Vogelzang, J Clin Oncol 1999 17 2506 2513 10561316 (Pubitemid 29368252)
22. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. DR Berthold GR Pond F Soban R de Wit M Eisenberger IF Tannock, J Clin Oncol 2008 26 242 245 10.1200/JCO.2007.12.4008 18182665
23. Docetaxel-based combination therapy for castration-resistant prostate cancer. MD Galsky NJ Vogelzang, Ann Oncol 2010 21 2135 2144 10.1093/annonc/ mdq050 20351071
24. Update on options for treatment of metastatic castration-resistant prostate cancer. P Vishnu WW Tan, Onco Targets Ther 2010 3 39 51 20616956
25. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. YM Ning JL Gulley PM Arlen S Woo SM Steinberg JJ Wright HL Parnes JB Trepel MJ Lee YS Kim H Sun RA Madan L Latham E Jones CC Chen WD Figg WL Dahut, J Clin Oncol 2010 28 2070 2076 10.1200/JCO.2009.25.4524 20308663
26. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. TM Beer CW Ryan PM Venner DP Petrylak GS Chatta JD Ruether KN Chi J Young WD Henner ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators, Cancer 2008 112 326 330 10.1002/cncr.23163 17960793
27. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. ME Taplin MM Regan YJ Ko GJ Bubley SE Duggan L Werner TM Beer CW Ryan P Mathew SM Tu SR Denmeade WK Oh O Sartor CS Mantzoros R Rittmaster PW Kantoff SP Balk, Clin Cancer Res 2009 15 7099 7105 10.1158/1078-0432.CCR-09-1722 19887483
28. Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. MD Galsky K Simon G Sonpavde TE Hutson M Fleming GV Kondagunta W Berry, Ann Oncol 2009 20 965 966 19403938
29. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. G Sonpavde PO Periman D Bernold D Weckstein MT Fleming MD Galsky WR Berry F Zhan KA Boehm L Asmar TE Hutson, Ann Oncol 2010 21 319 324 10.1093/annonc/mdp323 19633050
30. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. CN Sternberg DP Petrylak O Sartor JA Witjes T Demkow JM Ferrero JC Eymard S Falcon F Calabr N James I Bodrogi P Harper M Wirth W Berry ME Petrone TJ McKearn M Noursalehi M George M Rozencweig, J Clin Oncol 2009 27 5431 5438 10.1200/JCO.2008.20.1228 19805692
31. Update on tubulin binding agents. G Attard A Greystoke S Kaye J de Bono, Pathol Biol (Paris) 2006 54 72 84
32. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract]. AW Aller LA Kraus M-C Bissery, Proc Am Assoc Cancer Res 2000 41 303
33. Preclinical evaluation of TXD258, a new taxoid [abstract]. MC Bissery H Bouchard JF Riou C Vrignaud J Combeau JD Bourzat A Commercon F Lavelle, Proc Am Assoc Cancer Res 2000 41 214
34. Cabazitaxel. MD Galsky A Dritselis P Kirkpatrick WK Oh, Nat Rev Drug Discov 2010 9 677 678 10.1038/nrd3254 20811375
35. Cabazitaxel [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US, LLC 2010
36. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. N Agarwal TE Hutson NJ Vogelzang G Sonpavde, Future Oncol 2010 6 665 679 10.2217/fon.10.48 20465382
37. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. CJ Ryan MR Smith L Fong JE Rosenberg P Kantoff F Raynaud V Martins G Lee T Kheoh J Kim A Molina EJ Small, J Clin Oncol 2010 28 1481 1488 10.1200/JCO.2009.24.1281 20159824
38. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. G Attard AH Reid TA Yap F Raynaud M Dowsett S Settatree M Barrett C Parker V Martins E Folkerd J Clark CS Cooper SB Kaye D Dearnaley G Lee JS de Bono, J Clin Oncol 2008 26 4563 4571 10.1200/JCO.2007.15.9749 18645193
39. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. HI Scher TM Beer CS Higano A Anand ME Taplin E Efstathiou D Rathkopf J Shelkey EY Yu J Alumkal D Hung M Hirmand L Seely MJ Morris DC Danila J Humm S Larson M Fleisher CL Sawyers Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium, Lancet 2010 375 1437 1446 10.1016/S0140-6736(10)60172-9 20398925
40. Steroid hormone receptors in prostate cancer: a hard habit to break? G Attard CS Cooper JS de Bono, Cancer Cell 2009 16 458 462 10.1016/j.ccr.2009.11. 006 19962664
41. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. C Tran S Ouk NJ Clegg Y Chen PA Watson V Arora J Wongvipat PM Smith-Jones D Yoo A Kwon T Wasielewska D Welsbie CD Chen CS Higano TM Beer DT Hung HI Scher ME Jung CL Sawyers, Science 2009 324 787 790 10.1126/science. 1168175 19359544
42. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. PW Kantoff CS Higano ND Shore ER Berger EJ Small DF Penson CH Redfern AC Ferrari R Dreicer RB Sims Y Xu MW Frohlich PF Schellhammer IMPACT Study Investigators, N Engl J Med 2010 363 411 422 10.1056/NEJMoa1001294 20818862
43. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. PW Kantoff TJ Schuetz BA Blumenstein LM Glode DL Bilhartz M Wyand K Manson DL Panicali R Laus J Schlom WL Dahut PM Arlen JL Gulley WR Godfrey, J Clin Oncol 2010 28 1099 1105 10.1200/JCO.2009.25.0597 20100959
44. Emerging vaccine therapy approaches for prostate cancer. G Sonpavde KM Slawin DM Spencer JM Levitt, Rev Urol 2010 12 25 34 20428291
45. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. R Warren G Liu, Expert Opin Investig Drugs 2008 17 1237 1245 10.1517/13543784.17.8.1237 18616419
46. Zibotentan for the treatment of castrate-resistant prostate cancer. DR Shepard R Dreicer, Expert Opin Investig Drugs 2010 19 899 908 10.1517/13543784.2010.491822 20497097
47. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. ND James A Caty M Borre BA Zonnenberg P Beuzeboc T Morris D Phung NA Dawson, Eur Urol 2009 55 1112 1123 10.1016/j.eururo.2008.11. 002 19042080
48. Johnson & Johnson Press Release. 2010
49. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. VJ Sinibaldi, Clin Interv Aging 2007 2 555 560 18225455
50. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. L Zhao BY Lee DA Brown MP Molloy GM Marx N Pavlakis MJ Boyer MR Stockler W Kaplan SN Breit RL Sutherland SM Henshall LG Horvath, Cancer Res 2009 69 7696 76703 10.1158/0008-5472.CAN-08-4901 19773444
51. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. AJ Armstrong PG Febbo, Oncologist 2009 14 816 827 19684076